GKOS vs PATH · rev $383.5M vs P/E 19, rev $1.61B
Glaukos Corp (GKOS) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Glaukos Corp (GKOS) is a medical devices company listed on NYSE.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported GKOS revenue for 2024-12-31 was $383.5M. Net income was -$146.4M. Revenue was up 21.9% from 2023-12-31 to 2024-12-31. GKOS currently screens at market cap $7.63B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
GKOS currently screens at market cap $7.63B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the GKOS and PATH stock pages for the full models.
Not investment advice.